申请人:MERCK FROSST CANADA INC.
公开号:EP0147217A2
公开(公告)日:1985-07-03
Compounds having the formula:
and their pharmaceutically acceptable salts are antagonists of leukotrienes of C4, D4 and E4, the slow reacting substance of anaphylaxis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory agents, and cytoprotective agents. In the formula,
X is 0, S, SO, S02;
R is selected from:
-CH=CH-(C1 to C14 alkyl),
-(CH=CH)2-(C1 to C12 alkyl),
-(CH=CH)3-(C, to C10 alkyl),
-(CH=CH)3-(CH2-CH=CH)2-(C1 to C4 alkyl),
-(CH=CH)4-(C, to C8 alkyl),
-CH2-(CH=CH)4-(C1 to C7 alkyl),
-(CH=CH)3-CH2CH=CH-(CH2)nCH2OH wherein n is 1 to 6,
-(CH=CH)3-CH2CH=CH-(CH2)nCOOR1 wherein n is 1 to 6,
-(CH=CH)3-CH2CH=CH-(C1 to C7 alkyl);
-C≡C-(C1 to C14 alkyl),
-CH=CH-C≡C-(C1 to C12 alkyl),
-C≡C-(CH=CH)-(C1 to C12 alkyl),
-C≡C-(CH-CH)2-(C1 to Clo alkyl), and
-C≡C-(CH=CH)2-CH2-CH=CH-(C1 to C7 alkyl);
R1 is COOR", CH2OH, CHO, tetrazole, hydroxymethyl ketone, CN, CON(R4)2, CONHSO2R5 a monocyclic or bicyclic heterocyclic ring containing an acidic hydroxyl group or NHSO2R5; or
wherein each s is independently 0 to 3;
R9 is
A) a monocyclic or bicyclic heterocyclic radical containing from 3 to 12 nuclear carbon atoms and 1 or 2 nuclear heteroatoms selected from N and S with at least one being N, and with each ring in the heterocyclic radical being formed of 5 or 6 atoms, or
B) the radical W-R10 wherein W is O, S or NH and R10 contains up to 21 carbon atoms which may be straight chain or branched and is (1) a hydrocarbon radical or (2) an acyl radical of an organic cyclic or monocyclic carboxylic acid containing not more than 1 heteroatom selected from N, O or S in the ring;
each R8 is independently H or alkyl of 1 to 4 carbons which may be straight chain or branched;
or
R3 is H, lower alkyl, -(CH2)aCOOR1 or C1 to C5 acyl;
each R" is independently H, lower alkyl or two R4 radicals may be joined to from a ring of from 5 to 8 members;
each R5 is independently lower alkyl; CF3; phenyl; or substituted phenyl, wherein the substituents are C, to C3 alkyl, halogen, CN, CF3, COOR4 or C, to C3 alkoxy;
R6 is H, lower alkyl, OH, halogen, C, to C3 perfluoroalkyl, CN, NO2, C1 to C5 acyl, COOR4, SO2N(R4)2, N(R 4)2, ORS, SRS, SORS, SO2R5, 0-aryl, benzyl, benzyl substituted as defined for phenyl in R5, or CH2OH;
R7 is H or R5;
R" is H, lower alkyl, phenyl-lower alkyl, lower alkoxy-lower alkyl, lower acyloxy-lower alkyl;
a is 0 to 4.
具有以下式子的化合物
及其药学上可接受的盐类是白三烯 C4、D4 和 E4(过敏性休克的慢反应物质)的拮抗剂。这些化合物可用作抗哮喘、抗过敏、抗炎和细胞保护剂。在配方中
X 是 0、S、SO、S02;
R 选自
-CH=CH-(C1 至 C14 烷基)、
-(CH=CH)2-(C1 至 C12 烷基)、
-(CH=CH)3-(C10 至 C10 烷基)、
-(CH=CH)3-(CH2-CH=CH)2-(C1 至 C4 烷基)、
-(CH=CH)4-(C, to C8 烷基)、
-CH2-(CH=CH)4-(C1 至 C7 烷基)、
-(CH=CH)3-CH2CH=CH-(CH2)nCH2OH,其中 n 为 1 至 6、
-(CH=CH)3-CH2CH=CH-(CH2)nCOOR1,其中 n 为 1 至 6、
-(CH=CH)3-CH2CH=CH-(C1 至 C7 烷基);
-C≡C-(C1 至 C14 烷基)、
-CH=CH-C≡C-(C1 至 C12 烷基)、
-C≡C-(CH=CH)-(C1 至 C12 烷基)、
-C≡C-(CH-CH)2-(C1 至 Clo 烷基),以及
-C≡C-(CH=CH)2-CH2-CH=CH-(C1 至 C7 烷基);
R1 是 COOR"、CH2OH、CHO、四唑、羟甲基酮、CN、CON(R4)2、含有酸性羟基的单环或双环杂环的 CONHSO2R5 或 NHSO2R5;或
其中每个 s 独立地为 0 至 3;
R9 是
A) 单环或双环杂环基,含有 3 至 12 个核碳原子和 1 或 2 个核杂原子,杂原子选自 N 和 S,其中至少一个为 N,且杂环基中的每个环由 5 或 6 个原子组成,或
B) 自由基 W-R10,其中 W 是 O、S 或 NH,R10 含有多达 21 个碳原子,可以是直链或支链,并且是 (1) 碳氢自由基或 (2) 有机环状或单环羧酸的酰基,在环中含有不超过 1 个选自 N、O 或 S 的杂原子;
每个 R8 独立地为 H 或 1 至 4 个碳原子的烷基,可以是直链或支链;
或
R3 是 H、低级烷基、-(CH2)aCOOR1 或 C1 至 C5酰基;
每个 R "独立地为 H、低级烷基或两个 R4 自由基可连接成一个由 5 至 8 个成员组成的环;
每个 R5 独立地为低级烷基;CF3;苯基;或取代苯基,其中取代基为 C 至 C3 烷基、卤素、CN、CF3、COOR4 或 C 至 C3 烷氧基;
R6 是 H、低级烷基、OH、卤素、C 至 C3 全氟烷基、CN、NO2、C1 至 C5酰基、COOR4、SO2N(R4)2、N(R4)2、ORS、SRS、SORS、SO2R5、0-芳基、苄基、R5 中定义为苯基的取代苄基或 CH2OH;
R7 是 H 或 R5;
R" 是 H、低级烷基、苯基-低级烷基、低级烷氧基-低级烷基、低级酰氧基-低级烷基;
a 是 0 至 4。